Gil Blum, an analyst from Needham, reiterated the Buy rating on Sarepta Therapeutics (SRPT – Research Report). The associated price target was ...
Piper Sandler analyst Biren Amin lowered the firm’s price target on Sarepta (SRPT) to $182 from $200 and keeps an Overweight rating on the ...
The Dow Jones rose Wednesday ahead of the Federal Reserve's favored inflation gauge. Nvidia stock extended its recent losses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback